Search research articles
Contact Us
Filters
Showing results (271-280 of 346) with videos related to
Page
of 35
Sort By:
American Journal of Hematology
|
October 18, 2018
A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents
Nicholas J Short, Elias Jabbour, Kiran Naqvi, et al.
The Lancet. Haematology
|
February 5, 2024
Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study
Alex Bataller, Guillermo Montalban-Bravo, Alexandre Bazinet, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 22, 2026
Investigational clinical trial agents versus conventional second salvage therapies in patients with relapsed/refractory acute myeloid leukemia
Daniel Nguyen, Hagop M Kantarjian, Aram Bidikian, et al.
Cancer
|
October 29, 2020
Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations
Mahran Shoukier, Tapan Kadia, Marina Konopleva, et al.
American Journal of Hematology
|
June 19, 2023
Evolving trends and outcomes in older patients with acute myeloid leukemia including allogeneic stem cell transplantation
Alexandre Bazinet, Hagop Kantarjian, Naszrin Arani, et al.
Blood Advances
|
November 2, 2022
Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML
Ghayas C Issa, Aram Bidikian, Sangeetha Venugopal, et al.
JCO Oncology Practice
|
July 16, 2024
Outcomes of Patients With Newly Diagnosed AML and Hyperleukocytosis
Fadi G Haddad, Koji Sasaki, Jayastu Senapati, et al.
Journal of Hematology & Oncology
|
June 17, 2026
Final analysis of phase 2 clinical trial of ruxolitinib and azacitidine combination therapy in patients with myelodysplastic syndrome/myeloproliferative neoplasms
Sankalp Arora, Jayastu Senapati, Indraneel Deshmukh, et al.
Journal of Hematology & Oncology
|
January 30, 2022
Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure
Nicholas J Short, Sangeetha Venugopal, Wei Qiao, et al.
Cancer
|
August 3, 2021
Ten-day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity score-matched analysis
Abhishek Maiti, Courtney D DiNardo, Wei Qiao, et al.
Page
of 35
Search research articles
Search
Showing results (271-280 of 346) with videos related to
Sort By:
Page
of 35
American Journal of Hematology
|
October 18, 2018
A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents
Nicholas J Short, Elias Jabbour, Kiran Naqvi, et al.
The Lancet. Haematology
|
February 5, 2024
Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study
Alex Bataller, Guillermo Montalban-Bravo, Alexandre Bazinet, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 22, 2026
Investigational clinical trial agents versus conventional second salvage therapies in patients with relapsed/refractory acute myeloid leukemia
Daniel Nguyen, Hagop M Kantarjian, Aram Bidikian, et al.
Cancer
|
October 29, 2020
Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations
Mahran Shoukier, Tapan Kadia, Marina Konopleva, et al.
American Journal of Hematology
|
June 19, 2023
Evolving trends and outcomes in older patients with acute myeloid leukemia including allogeneic stem cell transplantation
Alexandre Bazinet, Hagop Kantarjian, Naszrin Arani, et al.
Blood Advances
|
November 2, 2022
Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML
Ghayas C Issa, Aram Bidikian, Sangeetha Venugopal, et al.
JCO Oncology Practice
|
July 16, 2024
Outcomes of Patients With Newly Diagnosed AML and Hyperleukocytosis
Fadi G Haddad, Koji Sasaki, Jayastu Senapati, et al.
Journal of Hematology & Oncology
|
June 17, 2026
Final analysis of phase 2 clinical trial of ruxolitinib and azacitidine combination therapy in patients with myelodysplastic syndrome/myeloproliferative neoplasms
Sankalp Arora, Jayastu Senapati, Indraneel Deshmukh, et al.
Journal of Hematology & Oncology
|
January 30, 2022
Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure
Nicholas J Short, Sangeetha Venugopal, Wei Qiao, et al.
Cancer
|
August 3, 2021
Ten-day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity score-matched analysis
Abhishek Maiti, Courtney D DiNardo, Wei Qiao, et al.
Page
of 35